The FDA flagged a potential VEGF-related safety concern in its review of Summit Therapeutics and Akeso’s now-rejected ivonescimab program, according to the companies’ correspondence referenced in a report. The feedback raises questions about the viability of VEGF-linked safety for a broader bispecifics class. The rejection adds another regulatory headwind for developers targeting angiogenesis-linked mechanisms, particularly for next-generation bispecific antibodies that aim to combine immune engagement with tumor vascular signaling.